Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Jun 2 · below the Ichimoku cloud · RSI 42 · MACD above its signal
None of the 29 investors followed here reported a position in CVKD in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a CVKD trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 28, 2026 | Pham Quang XChief Executive Officer | Sale at price 3.03 per share. | 7.4K | $22.42K |
| Jun 25, 2026 | Pham Quang XChief Executive Officer | Sale at price 3.00 - 3.05 per share. | 11.2K | $33.92K |
| Jun 22, 2026 | Pham Quang XChief Executive Officer | Sale at price 3.20 - 3.55 per share. | 11.4K | $39.83K |
| Jun 16, 2026 | Pham Quang XChief Executive Officer | Sale at price 3.16 - 3.18 per share. | 4.1K | $13.11K |
| Jun 14, 2026 | Pham Quang XChief Executive Officer | Sale at price 3.58 - 4.12 per share. | 18.1K | $70.35K |
| Jun 9, 2026 | Pham Quang XChief Executive Officer | Sale at price 4.06 - 4.38 per share. | 22.4K | $93.29K |
| Jun 4, 2026 | Pham Quang XChief Executive Officer | Sale at price 4.26 - 4.42 per share. | 8.3K | $36.21K |
| Jun 1, 2026 | Pham Quang XChief Executive Officer | Sale at price 4.46 - 5.01 per share. | 652 | $3.08K |
| May 27, 2026 | Pham Quang XChief Executive Officer | Sale at price 4.93 - 5.76 per share. | 12.8K | $69.45K |
| May 21, 2026 | Pham Quang XChief Executive Officer | Sale at price 5.69 per share. | 1.2K | $6.63K |
| Dec 28, 2025 | Szot Matthew KChief Financial Officer | Sale at price 6.97 per share. | 9.9K | $69.23K |
| Oct 26, 2025 | Szot Matthew KChief Financial Officer | Sale at price 13.99 per share. | 3.6K | $50.36K |
| Oct 26, 2025 | Pham Quang XChief Executive Officer | Sale at price 13.99 - 14.03 per share. | 2.4K | $34.24K |
| Oct 12, 2025 | Szot Matthew KChief Financial Officer | Sale at price 13.99 - 14.07 per share. | 3.5K | $49.01K |
| Oct 12, 2025 | Pham Quang XChief Executive Officer | Sale at price 14.02 - 14.15 per share. | 3.6K | $50.71K |
| Oct 5, 2025 | Szot Matthew KChief Financial Officer | Sale at price 13.99 per share. | 107 | $1.50K |
| Oct 1, 2025 | Pham Quang XChief Executive Officer | Sale at price 14.13 per share. | 500 | $7.07K |
| Sep 30, 2025 | Szot Matthew KChief Financial Officer | Sale at price 13.99 - 14.00 per share. | 1.8K | $25.18K |
| Sep 30, 2025 | Pham Quang XChief Executive Officer | Sale at price 14.01 per share. | 1.3K | $18.21K |
| Sep 24, 2025 | Szot Matthew KChief Financial Officer | Sale at price 14.00 - 14.05 per share. | 12.4K | $174.18K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.5 | 22.2 | -39.7 | 30.3 | -25.6 | -32.7 | -39.8 | -12.9 | -38.3 | -5.6 | −85.0% | ||
| 2025 | 36.4 | -3.9 | -7.2 | -6.9 | -18.8 | -9.6 | -13.5 | 24.4 | 6.7 | -1.2 | -31.3 | -27.8 | −53.2% |
| 2024 | 145.9 | -61.3 | -13.4 | -27.9 | 7.0 | -0.2 | -7.7 | 17.0 | 79.3 | 24.2 | -10.4 | -4.6 | +30.5% |
| 2023 | -28.4 | -29.1 | -5.0 | 6.0 | 6.3 | -43.7 | -9.4 | -11.7 | -35.1 | 4.3 | 60.9 | −73.4% |
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Buy / hold / sell counts